Study your flashcards anywhere!

Download the official Cram app for free >

  • Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key

image

Play button

image

Play button

image

Progress

1/33

Click to flip

33 Cards in this Set

  • Front
  • Back
(amount of drug)/(fluid compartment concentration)
Vd
protein bound drugs
liver and kidney disease
pharmacodynamic variable altered?
Vd
Vd eq
Vd = drug amount/drug concentration
Cl eq
Cl = elimination rate/[drug]
t1/2 eq
t1/2 = .7*Vd/Cl
10% remaining concentration
# half lives?
3.3
12.5% remaining concentration
# half lives?
3
25% remaining concentration
# half lives?
2
Loading dose eq
Loading dose = Cp*Vd/F
Maintenance dose eq
Maintanence Dose = Cp*CL/F

Cp= target [drug]
F = bioavailability
change in loading dose with renal/hepatic disease
Unchanged
change in maintanence dose with renal/hepatic disease
lower
zero order elimination
constant __ of drug eliminated per time
amount
first order elimination
constant __ of drug eliminated per time
fraction
zero order elimitation
Cp decreases linearly/exponentially?
linearly
first order elimination
Cp decreases linearly/exponentially?
exponentially
Phase I metabolism
resulting metabolite characteritics
slightly polar
water soluble
often still active
Phase I metabolism reactions
oxidation
reduction
hydrolysis
oxidation
reduction
hydrolysis

Phase?
Phase I
cytochrome P-450
phase?
Phase I
Phase II metabolism
resulting metabolite characteristics
very polar
inactive
*renally excreted
Phase II metabolism reactions
acetylation
glucuronidation
sulfanation
acetylation
glucuronidation
sulfanation

Phase?
Phase II
conjugation

Phase?
Phase II
Phase metabolism lost in geriatrics
Phase I
competitive antagonist effect on agonist dose curve
shift to right
**decreased potency
noncompetitive antagonist effect on agonist dose curve
shifts downward
**decreased efficacy
EC50 vs Kd in system w/ spare receptors
EC50 < Kd
partial agonist vs full agonist
less efficacy
phase 1 clinical trial questions
is it safe?
pharmacokinetics?
Phase 2 clinical trial questions?
does it work in patients?
Phase 3 clinical trial questions?
Does it work double blind?
Phase 4 clinical trial questions?
Postmarketing is it safe?